News by Tag: Bioavailability
Congress on Pharmaceutical r & d summit
January 5, 2013
The absence of a significant difference in the rate of active ingredient pharmaceutical equivalents or pharmaceutical alternative at site of action is applicable, is defined as bioequivalence.
January 5, 2013
The absence of a significant difference in the rate of active ingredient pharmaceutical equivalents or pharmaceutical alternative at site of action is applicable, is defined as bioequivalence.